[Chosun Biz][Law Firm Practice Skills] Lee & Ko Protects Boryung Pharmaceutical’s Right in Hypertension Treatment with KRW 50 Billion in Sales

On January 8, 2024, Chosun Biz reported Lee & Ko’s recent win for Boryung Pharmaceutical, noting that “as the efficacy of Dukarb®, Boryung’s hypertension drug, went viral, it became the target of other Korean pharmaceutical companies” but “Boryung has defended its Dukarb® patent all the way from the Intellectual Property Trial and Appeal Board stage to the ensuing trials, with Lee & Ko’s Healthcare Practice Group, led by Ms. Keum Nang Park, playing a key role in the defense.”  Ms. Park remarked in an interview that “this is the first time a Korean pharmaceutical company that has developed an original drug defended its patent rights in a large-scale dispute against multiple generic companies,” further noting that “we felt that this drug should be afforded patent protection especially since it was a new drug developed after many challenges in Korea, where new drug R&D is still rare.”